Nalu Bio, Inc.

CAMBRIDGE, England and WILMINGTON, Del., Sept. 29, 2026 /PRNewswire/ -- Cyted Health, a leading gastrointestinal molecular diagnostics company, today announced the appointment of Thomas West as Chair of its Board of Directors and Non-Executive Director, and the appointment of Robert Epstein as a Non-Executive Director, to support the company's continued commercial growth across the US and UK. West is a seasoned medtech executive with more than 35 years of experience leading and advising medtech organizations. He served as President, CEO and Director of Nalu Medical, a neurostimulation device company providing solutions for chronic pain, which was acquired by Boston Scientific in January 2026 for $600 million. Prior to Nalu, West was the President and CEO of Intersect ENT, an ear, nose and throat company, which was sold to Medtronic for $1.1 billion in May 2022. He led Hologic's global molecular diagnostic business and has broad healthcare experience from his 23-year tenure with Johnson & Johnson. West serves on the Boards of Directors of Ceribell (neurologic conditions), SI-BONE (orthopedic implants) and ViCentra (diabetes). Epstein similarly brings more than 35 years of leadership and advisory experience across diagnostics, life sciences and healthcare. He is Chairman of the Board at Veracyte, a genomic diagnostics company, and serves on the Boards of Fate Therapeutics, Tasso Inc, PinxDx and the Estonian Multiomics Company (EMC). He previously served on the Board of Illumina and chaired Decipher Biosciences before its acquisition by Veracyte. Earlier in his career, Epstein spent more than two decades at Medco Health Solutions, including as Chief Medical Officer and Chief Research and Development Officer. "Cyted's Board gets stronger today with Tom joining as Chair and Robert as a Non-Executive Director," said Marcel Gehrung, CEO and Co-founder of Cyted Health. "Their appointments significantly strengthen the Board as we enter our next phase of growth. Together, they bring the strategic and operational expertise needed to support Cyted in expanding adoption of our technology. I also want to thank our previous Chair, Gail Marcus, for her leadership and invaluable contributions in helping Cyted reach so many important clinical and commercial milestones." About Cyted Health Cyted Health believes early and accurate identification of esophageal disease can change the clinical clock - bringing clarity sooner, so clinicians can act earlier with greater impact. The company is dedicated to improving early detection and prevention of esophageal adenocarcinoma. Its platform combines minimally invasive cell collection with high-resolution molecular analysis to detect early biological changes associated with Barrett's esophagus and cancer. Cyted Health has built a robust portfolio of peer-reviewed publications and conducted over 40,000 tests using its diagnostic platform. Cyted Health cares about restoring time when medicine does its best work: clearer answers, more informed decisions, and fewer patients left waiting in anxiety, so more people can get back to life, facing forward with confidence not concern. SOURCE Cyted Health 21% more press release views with Request a Demo

Medtronic has announced plans to acquire privately held medtech company SPR Therapeutics, a leader in temporary percutaneous peripheral nerve stimulation therapies for chronic pain management. Medtronic will acquire the company for $650 million, further building out its core neuromodulation franchise. The 50-year-old neuromodulation division includes the industry's broadest pain therapy portfolio, and the new acquisition will complement Medtronic’s existing minimally invasive pain relief options for patients earlier in their care continuum. SPR’s patented technologies include the FDA-cleared SPRINT PNS System, a short-term, 60-day therapy designed to provide pain relief through a temporary treatment approach that does not require a permanent implant. The therapy integrates into existing clinical workflows and enables physicians to intervene earlier, expanding patient access. "Our purpose first and foremost is to serve patients," Domenico De Paolis, Interim President Neuromodulation, part of the Medtronic Neuroscience Portfolio, said in a prepared statement. "That is why we continue to thoughtfully expand our pain intervention therapies. The addition of temporary peripheral nerve stimulation helps broaden access to neuromodulation and supports patients across more stages of the chronic pain journey with a minimally invasive therapy." The largest retrospective review of real-world PNS data to date was conducted using the SPRINT PNS System. The study included more than 6,100 patients, and showed over 71% of study participants demonstrated significant pain relief and/or improvement in quality of life following 60-day percutaneous PNS treatment. Subject to regulatory approvals, the acquisition is expected to close in the first half of Medtronic’s Fiscal Year 2027. This is not Medtronic’s first big name interaction of the last year. The company has been redhot on acquisitions since Q4 2025. In March, the Galway, Ireland-based medtech giant just announced plans to acquire Scientia Vascular in a deal valued at $550 million, with potential undisclosed earn-out and milestone payments post-acquisition. This deal follows Medtronic’s announcement in early February that it intended to acquire CathWorks in a deal valued at $583 million. That deal also has potential post-acquisition undisclosed earn-out payments baked into it. In April, the medical device giant acquired an AI-powered coronary assessment company for $585M and led a $100M strategic round for a pulmonary hypertension therapy pioneer. At the beginning of the year, CEO Geoff Martha announced that Medtronic is going on the offense with strategic M&A for 2026. He talked about the company's four big "generational growth drivers." These include pulsed field ablation technologies, renal denervation, tibial neuromodulation for urge urinary incontinence, and robotic-assisted surgery. While Medtronic is no doubt a big player in the PNS space, it is not entirely free from competition. In October, Boston Scientific announced plans to acquire medtech company Nalu Medical, which specializes in developing and commercializing minimally invasive chronic pain solutions. Boston Scientific has been a Nalu investor since 2017, already holding an equity stake in the company. It purchased the remaining equity for $533 million. Nalu’s neurostimulation system delivers relief for adults living with severe, intractable chronic pain of peripheral nerve origin, including areas such as the shoulder, lower back and knee, through peripheral nerve stimulation, by using mild electrical impulses to interrupt pain signals before they reach the brain. The system is made of a miniaturized battery-free implantable pulse generator, powered wirelessly by a small, externally worn therapy disc and controlled via a smartphone app. The pain system first received FDA clearance in 2019 following two randomized clinical trials in which 87% of participants reported more than a 50% reduction in pain at 12 months. Additional real-world data shows that out of 2,000 patients, 94% achieved clinically meaningful improvement across a broad range of chronic peripheral nerve pain conditions. The PNS market is valued at roughly $688 million currently, and is expected to surpass $1 billion by the early 2030s. With that momentum and market growth expected, there will likely be new competitors in the space shortly, with Medtronic and Boston Scientific fighting to hold the lead in PNS.

Boston Scientific Corporation secured net sales of $5.203 billion during the first quarter of 2026, growing 11.6% overall. The company’s guidance predicted 10.5% to 12% growth for the period. In addition, the company’s MedSurg segment posted 7.8% growth, while its cardiovascular segment posted 13.5% growth. Amid growing competition in the cardiovascular space, and a recent shareholder lawsuit over inflated Electrophysiology results, this growth is a good sign for both the company and its investors. Despite the growing competition, Boston Scientific has managed to retain its place on the list of the top nine cardiovascular device companies in the world in 2026. The global cardiovascular devices market size was valued at $53.67 billion in 2024 and is anticipated to grow at a CAGR of 8.4% from 2025 to 2030. WATCHMAN FLX, EKOS, and FARAPULSE studies demonstrate clinical superiority During Q1 2026, the company also made several strides in its cardiology portfolio. Research presented at the American College of Cardiology’s annual meeting demonstrated that the WATCHMAN FLX Left Atrial Appendage Closure Device as a first-line option for stroke risk reduction met all primary and secondary endpoints and demonstrated superior bleeding risk reduction and similar efficacy of the WATCHMAN FLX device compared to oral anticoagulants in a broad population of patients with non-valvular atrial fibrillation. A second study demonstrated that the EKOS Endovascular System for the treatment of acute pulmonary embolism (PE) in patients with intermediate-risk PE demonstrated the EKOS system plus anticoagulation was superior to anticoagulation alone. The company also announced positive outcomes from the ADVENT Long-Term Outcomes clinical trial, which demonstrated greater long-term AF treatment success, fewer hospital-based arrhythmia interventions and lower repeat ablation rates at four years with FARAPULSE Pulsed Field Ablation (PFA) compared to thermal ablation , received National Medical Products Association approval in China for the OPAL HDx Mapping System, which enables catheter visualization during FARAPULSE PFA procedures, and determined that patients found statistically significant pain relief and improved quality of life with peripheral nerve stimulation therapy with the Nalu Neurostimulation System compared to conventional medical management in patients with chronic pain. Boston Scientific completes Valencia technologies acquisition, advances Penumbra deal This quarter, Boston Scientific also completed the acquisition of Valencia Technologies Corporation , a privately held company focused on the development and commercialization of the eCoin System, an implantable tibial nerve stimulation device for the treatment of urge urinary incontinence. In the same quarter, Boston Scientific also announced plans to acquire Penumbra , and officially acquired Nalu . The company now estimates net sales growth for the full year 2026, versus the prior year period, to be approximately 7% to 8.5%. The company estimates net sales growth for the second quarter of 2026, versus the prior year period, to be approximately 5.5% to 7.5%. Company lowers full-year 2026 guidance to 7-8.5% growth This guidance is down from Boston Scientific’s original guidance of 8.5% to 10% full year growth. The company also said its outlook excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures. Analysts at BTIG still remain strong on the stock, holding a buy rating, despite adjusting the company’s price target from $90 to $110. "Our global team and the strength of our category leadership strategy enabled us to deliver solid results this quarter," Mike Mahoney, chairman and CEO of Boston Scientific, said in a prepared release. "We remain focused on executing our long-term strategy and advancing our differentiated pipeline to drive meaningful impact for patients, physicians and hospital systems." Following the release of Q1 2026 results, the company’s stock jumped 10%. This is the third quarter in a row that high sales and growth for Boston Scientific have been led by its cardiovascular segment . Electrophysiology segment faces headwinds from PFA competition Investors should, however, remain leery of its Electrophysiology segment performance following the aforementioned shareholder lawsuit. In February, Boston Scientific missed consensus for its electrophysiology segment by $33 million due to increased competition in the pulsed-field ablation market. Marie Thibault, a BTIG analyst, wrote, “The closely watched electrophysiology segment missed consensus by $33 million, confirming investor fears.” Because of the sales miss, BTIG analysts readjusted their forecast for the electrophysiology segment. “We reduce our electrophysiology revenue forecast and increase our ICVT outlook,” Thibault wrote. “We now model 17% year over year worldwide sales growth for EP, reflecting estimates for 13% U.S. year-over-year EP sales growth and 25% OUS year-over-year EP sales growth.” Thibault also wrote, “Boston Scientific has dazzled investors in the past with its one-two punch of Farapulse and Watchman, but we think that era is likely behind us.”